Seattle Genetics Inc. sees its antibody drug conjugate Adcetris (brentuximab vedotin) as setting a new standard of care in the frontline treatment of classical Hodgkin lymphoma following US FDA approval for use with chemotherapy in previously untreated Stage III and Stage IV disease on March 20.
Seattle Genetics Says Adcetris Sets New Standard In Frontline Lymphoma
The market for a new FDA-approved indication in frontline classical Hodgkin lymphoma could be worth $650m to $750m, some analysts say.
More from New Products
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
More from Scrip
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.